Harmony Biosciences (HRMY)
(Delayed Data from NSDQ)
$34.40 USD
-0.78 (-2.22%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $34.38 -0.02 (-0.06%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth A Momentum A VGM
Fundamental Charts
About Market Cap
As of the previous market close, Harmony Biosciences Holdings, Inc. has a market cap of $2.02B, which represents its share price of $35.18 multiplied by its outstanding shares number of 57.42M. As a mid-cap company, HRMY's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
HRMY 34.40 -0.78(-2.22%)
Will HRMY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for HRMY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HRMY
Analysts Estimate Stoke Therapeutics, Inc. (STOK) to Report a Decline in Earnings: What to Look Out for
Harmony Biosciences Holdings, Inc. (HRMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
HRMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
REGN Q2 Earnings: Will Higher Dupixent Profits Fuel Growth?
Tenet Beats Q2 Earnings on Strong Patient Volumes, Hikes '25 EPS View
5 High Earnings Yield Stocks to Tap Into Value Investing Gains
Other News for HRMY
Harmony Biosciences Holdings Inc (HRMY) to Announce Q2 2025 Financial Results | HRMY stock news
Harmony Biosciences to Report Second Quarter 2025 Financial Results on August 5, 2025 | HRMY ...
Truist Securities Initiates Coverage on Harmony Biosciences (HRMY) with Buy Rating | HRMY Stock News
Truist Initiates Buy Rating for Harmony Biosciences (HRMY) with Promising Growth Prospects | ...
Harmony Biosciences initiated with bullish view at Truist, here's why